Laparoscopic versus robot-assisted left-sided pancreas removal for benign and premalignant lesions
Official title: Laparoscopic Versus Robot-assisted Left-sided Pancreatectomy for Benign and Pre-malignant Lesions (DIPLOMA-3): an International Multicenter Patient-blinded Randomized Controlled Trial
Run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · NCT06939023 · Data updated 2026-11-12
This trial will randomize adults needing elective left-sided pancreas removal for benign or premalignant lesions to laparoscopic or robot-assisted minimally invasive surgery to see if one approach leads to faster recovery and fewer complications.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 256 (estimated) |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Academic / other |
| Locations | 1 site (Amsterdam) |
| Status | Recruiting |
| Started | June 1, 2025 |
| Main results expected | June 1, 2027 |
| Study ends | June 1, 2028 |
| Registry record updated | September 4, 2025 |
| Trial ID | NCT06939023 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with benign or premalignant lesions in the pancreas body or tail who are fit for elective left-sided pancreatectomy, for whom both laparoscopic and robot-assisted approaches are technically feasible, and who provide informed consent.
✕Probably not a fit
Patients with suspected pancreatic ductal adenocarcinoma, tumors larger than 8 cm, major vascular involvement, need for resection/ablation of other organs, pregnancy, BMI >40 kg/m2, or participation in conflicting trials are excluded and unlikely to benefit from this comparison.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The DIPLOMA-3 trial is an international, multicenter, patient-blinded randomized controlled comparison of laparoscopic and robot-assisted left-sided pancreatectomy for benign or premalignant lesions in the body or tail of the pancreas. Eligible adults are randomized to undergo either laparoscopic or robot-assisted minimally invasive resection, with both spleen-preserving and non-preserving procedures allowed where appropriate. Surgeons must deem both approaches technically feasible for each patient, and standard perioperative care and follow-up protocols are applied across participating centers. Outcomes focus on perioperative complications, recovery metrics, and surgical safety to determine whether one minimally invasive approach has clinical advantages.
Why it matters
Potential benefit: If successful, the trial could clarify whether robot-assisted or laparoscopic techniques lead to fewer complications, quicker recovery, or better spleen preservation after left-sided pancreas removal.
How similar studies have gone: Laparoscopic distal pancreatectomy has demonstrated safety and effectiveness in prior studies and robot-assisted techniques have encouraging observational results, but randomized evidence directly comparing the two approaches is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age at least 18 years; * Indication for elective left-sided pancreatectomy, either spleen-preserving or non-preserving (because of proven or suspected left-sided benign or premalignant disease); * Both robot-assisted and laparoscopic left-sided pancreatectomy are technically feasible for resection, according to the local treatment team; * Fit to undergo left-sided pancreatectomy according to the surgeon and anaesthesiologist; * Written informed consent Exclusion Criteria: * Suspected pancreatic ductal adenocarcinoma; * Tumor or cyst larger than 8 cm; * Required resection or ablation of organs other than pancreas and spleen; * Tumor involvement or abutment of major vessels (celiac trunk, mesenteric artery or vena cava); * Pregnancy; * Body mass index \>40 kg/m2; * Participation in another study with interference of study outcomes
Where it's running
-
Amsterdam UMC
Amsterdam, Netherlands Recruiting
Study contacts
- Principal investigator: Prof. Mohammad Abu Hilal, MD PhD — University of Jordan
- Study coordinator: Charlotte Baggerman van Houweninge, MD
- Email: c.e.baggermanvanhouweninge@amsterdamUMC.nl
- Phone: +31618037377
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pancreatic Surgery and New Diabetes Risk in Adults without Diabetes
This study tests whether removing part or all of the pancreas during surgery affects blood sugar control and metabolism in adults who did not have diabetes before the operation.
-
Robot-assisted versus open lateral pancreaticojejunostomy for symptomatic chronic pancreatitis
This trial will test whether robot-assisted or open lateral pancreaticojejunostomy leads to better early recovery for adults with chronic pancreatitis and a dilated main pancreatic duct.
-
Three-day discharge after distal pancreatectomy feasibility and effectiveness
This study tests whether selected patients can go home 3 days after a minimally invasive distal pancreatectomy and still do well.
-
Registry for pancreatic cysts at UCSF
This study is setting up a registry to track patients with pancreatic cysts to see how these cysts change over time and to help doctors make better treatment decisions.
-
Blood and cyst fluid analysis from patients undergoing pancreatic cyst surgery
Researchers will collect blood and cyst fluid from adults having pancreatic cysts surgically removed to test for DNA, RNA, and proteins.
-
Energy needs after pancreatic surgery: measuring metabolism to guide nutrition
This study tests how much energy patients need after pancreatic surgery and compares direct measurements with common estimating methods to see if standard formulas are accurate.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.